BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

Posted on by BIOVECTRA

BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

Charlottetown, Prince Edward Island, Canada (March 17, 2019) – BIOVECTRA Inc., a U.S. Food and Drug Administration- and Health Canada-inspected and approved Contract Development and Manufacturing Organization (CDMO), announces the offer of high quality, fully synthetic cGMP CBD API for clinical and commercial applications. BIOVECTRA’s efficient cGMP CBD manufacturing process allows for the production of hundreds of kilograms, with the ability to scale-up to multi-metric ton quantities. This scale-up and supporting regulatory experience is a key competency for BIOVECTRA, which can be applied to additional cannabinoid derivatives. Production is on-going for intermediate-scale batches, with process validation and submission of a Drug Master File to follow.

Located in Canada, BIOVECTRA is uniquely positioned as a global supplier of synthetic cGMP CBD. The company can offer material supply, as well as product storage services as required.

BIOVECTRA has a history of working in cannabinoids, dating back to the early 2000s, when it developed a supply of dronabinol. Building off its existing strengths in complex synthetic chemistry and natural product purifications, the company’s ability to manufacture synthetic cGMP CBD complements increased market demand. BioVectra looks forward to continuing to supply its current and new customers with this pharmaceutically important compound.

For more information, please contact BIOVECTRA at [email protected] or 866-883-2872 to discuss your CBD requirements.

About BIOVECTRA

BIOVECTRA is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BIOVECTRA has over 45 years of experience specializing in:

For more information about BIOVECTRA, please visit www.biovectra.com.

Contact

Fahim Naeem, Business Development Manager
BIOVECTRA Inc.
Phone: 866-883-2872
E-Mail: [email protected]

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors